|
PureTech Health PLC on Friday noted the pricing of its founded entity Seaport Therapeutics Inc for its planned initial public offering on the Nasdaq. The Boston, Massachusetts-based biotech and pharmaceutical company said Seaport’s upsized IPO is of around 14.2 million shares at a price to the public of $18.00 per share, at the top end of the target range. The gross proceeds to Seaport from the offering are expected to be $254.9 million. The shares are expected to start trading on the Nasdaq Global Select Market on Friday, with the offering anticipated to close on Monday. PureTech shares rose 8.9% to 138.91 pence each on Friday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
